米食品医薬品局(FDA)が、BRAF遺伝子変異陽性の切除不能または転移性の悪性黒色腫に対し、BRAF阻害薬encorafenib+MEK阻害薬binimetinib併用療法を承認【FDA】

FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations

On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

コメント

Leave a comment

Your email address will not be published.


*